Becton Dickinson partners with Washington for back-to-school COVID testing » 06:5109/2109/21/21
Becton Dickinson announced it has been selected by the state of Washington as a digitally read, rapid antigen test option for COVID-19 testing and screening in K-12 schools across the state.
|Over a month ago|
Becton Dickinson Covid test approval 'nice positive,' says Piper Sandler » 04:5708/2608/26/21
Piper Sandler analyst…
Piper Sandler analyst Jason Bednar keeps an Overweight rating on Becton Dickinson with a $285 price target after the company received emergency use authorization from the FDA for its Veritor At-Home COVID Test. The company disclosed that initial sales will be made to assist with reopening efforts at businesses, schools and governments, with additional details on pricing providing comfort Veritor should be competitive once launched in the coming months, says the analyst. He sees the announcement as a "nice positive" for Becton Dickinson.
Becton Dickinson's at-home COVID-19 test granted emergency use authorization » 16:1308/2508/25/21
Becton Dickinson's BD Veritor At-Home COVID-19 Test has received an Emergency Use Authorization from the FDA, the first at-home COVID-19 rapid antigen test to use computer vision technology in a smartphone to interpret and provide a digital display of testing results. BD developed this new digitally read, lateral flow antigen self-test to make COVID-19 testing faster and easier for people to complete in their own homes. The test will initially be made available to businesses, schools and governments. The BD Veritor At-Home COVID-19 Test will use a nasal swab and a mobile app from Scanwell Health that yields test results in 15 minutes.
Becton Dickinson announces Christopher DelOrefice as CFO » 06:0708/1108/11/21
Becton Dickinson (BDX)…
Becton Dickinson (BDX) announced that Christopher DelOrefice has been named executive vice president and chief financial officer, or CFO, effective September 6. DelOrefice succeeds Christopher Reidy, who announced his intent to retire from BD last week. DelOrefice, 50, will join BD from Johnson & Johnson (JNJ), where he is currently vice president of investor relations.
Becton Dickinson downgraded to Neutral at JPMorgan on 'muted' FY22 outlook » 09:5008/0608/06/21
As previously reported,…
As previously reported, JPMorgan analyst Robert Marcus downgraded Becton Dickinson to Neutral from Overweight with a price target of $265, down from $280. While Becton reported better than expected top and bottom-line Q3 results, this was overshadowed by the company's "muted" Q4 and FY22 outlook, Marcus tells investors. Though he had been expecting a soft FY22 outlook, the floor for FY22 EPS of $12.00 is "well below" the Street's forecast heading into the report and he is "struggling to fully understand why margins are taking so long to return to pre-COVID-19 levels," Marcus said.
Becton Dickinson downgraded to Neutral from Overweight at JPMorgan » 06:2908/0608/06/21
JPMorgan analyst Robert…
JPMorgan analyst Robert Marcus downgraded Becton Dickinson to Neutral from Overweight with a $265 price target.
Becton Dickinson FY22 earnings reset was necessary, says Piper Sandler » 13:5508/0508/05/21
Piper Sandler analyst…
Piper Sandler analyst Jason Bednar reiterated an Overweight rating and $285 price target on Becton Dickinson after the company reported Q3 results and provided an initial financial framework for fiscal 2022. The analyst said that the margin and earnings reset for FY22 was necessary, "as much as it may have been uncomfortable," though he sees this FY22 color as a potential clearing event for the stock. Bednar added that Becton Dickinson has been and will continue to be an execution-first story.
Becton Dickinson raises FY21 adj. EPS view to $12.85-$12.95 from $12.75-$12.85 » 06:0508/0508/05/21
Consensus $12.83. Raises…
Consensus $12.83. Raises FY21 revenue view to up 16.5%-17% from up 12%-14%, consensus $19.44B. The company said, "BD has updated its outlook for fiscal 2021 which reflects numerous assumptions about many factors that could affect its business based on the information management has reviewed as of this date, which includes observations and assumptions regarding the continued impact of the COVID-19 pandemic. The company's outlook continues to assume no major system-wide hospital restrictions on elective procedures related to the COVID-19 pandemic. However, in recent weeks the company started to see some impact on elective procedures from the COVID-19 delta variant in some states in the U.S. and assumes some continuation of this in its outlook. Management will discuss its outlook and several of its assumptions on its third fiscal quarter earnings call."
Becton Dickinson reports Q3 adjusted EPS $2.74, consensus $2.44 » 06:0308/0508/05/21
Reports Q3 revenue…
Reports Q3 revenue $4.89B, consensus $4.51B. "Our strong third quarter results reflect continued momentum across our base business," said Tom Polen, chairman, CEO and president of BD. "Solid execution by our teams has strengthened our foundation, while increased investment in R&D and tuck-in M&A are enhancing our innovation pipeline. We look forward to updating you on our innovation-driven BD 2025 strategy, which leverages our core strengths and market leadership positions to deliver long-term growth and value for all stakeholders at our Investor Day on November 12."
FDA posts letter on previous issues seen with Becton Dickinson COVID-19 test » 15:3307/2907/29/21
The U.S. Food and Drug…
The U.S. Food and Drug Administration had alerted clinical laboratory staff and health care providers of an increased risk of a false positive result with BD SARS-CoV-2 Reagents for the BD Max System test, the agency stated in a communication posted on its website. "On March 10, 2021, based on new data provided by Becton, Dickinson and Company, the FDA reissued the EUA for the BD SARS-CoV-2 Reagents for the BD Max System test, and the test no longer has an increased risk of false positive results. For updated labeling, including results of a post-authorization study, see the Instructions for Use. Accordingly, all safety concerns listed on this page have been resolved and the previous recommendations for clinical laboratory staff and health care providers no longer apply to the BD SARS-CoV-2 Reagents for the BD Max System test," the FDA posting dated July 29 stated.